个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共13条记录   Lixisenatide for type 2 diabetes mellitus [作者：Christensen, M; Knop, FK; Vilsboll, T; Holst, JJ,期刊：Expert opinion on investigational drugs, 页码：549-557 , 文章类型： Article，,卷期：2011年20-4] Areas covered: Pharmacological, preclinical and clinical evidence demonstrating the applicability of lixisenatide for the treatment of T2DM are reviewed. Available data and pending clinical development are summarized, cr... Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411 [作者：Uglietti, A; Maserati, R,期刊：Expert opinion on investigational drugs, 页码：559-565 , 文章类型： Article，,卷期：2011年20-4] Areas covered: Areas covered include preclinical, Phase I and Phase IIa studies of VS411, the first drug product in a novel class of anti-HIV drugs, AV-HALT agents. Expert opinion: The two drug combination VS411 safely a... S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges [作者：Lenz, JCC; Rockstroh, JK,期刊：Expert opinion on investigational drugs, 页码：537-548 , 文章类型： Article，,卷期：2011年20-4] Areas covered: A Pubmed and Medline search was carried out on all articles on S/GSK1349572 from 2005 to 2010, including recent abstract presentations from major HIV conferences (CROI 2010, WAC2010, EACS2009, HIV10 and IC... Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes [作者：Romualdi, E; Ageno, W,期刊：Expert opinion on investigational drugs, 页码：495-505 , 文章类型： Review，,卷期：2011年20-4] Areas covered: This review provides an overview of the two oral anti-FXa drugs at the most advanced stage of development (rivaroxaban and apixaban) and briefly describes and comments on the results of the most important ... New phosphatidylinositol 3-kinase inhibitors for cancer [作者：Bowles, DW; Jimeno, A,期刊：Expert opinion on investigational drugs, 页码：507-518 , 文章类型： Review，,卷期：2011年20-4] Areas covered: This article reviews current literature and recent conference proceedings to analyze the rationale for targeting PI3K and its downstream effectors in cancer. Preclinical and clinical results of several PI3... Epigenetic regulation in myelodysplastic syndromes: implications for therapy [作者：Vigna, E; Recchia, AG; Madeo, A; Gentile, M; Bossio, S; Mazzone, C; Lucia, E; Morabito, L; Gigliotti, V; De Stefano, L; Caruso, N; Servillo, P; Franzese, S; Fimognari, F; Bisconte, MG; Gentile, C; Morabito, F,期刊：Expert opinion on investigational drugs, 页码：465-493 , 文章类型： Review，,卷期：2011年20-4] Areas covered: This review provides an understanding of studies investigating novel agents published up to January 2011 aimed at normalizing and monitoring the epigenetic profile of the MDS cancer cell. The authors discu... Corticotropin releasing factor receptor antagonists for major depressive disorder [作者：Paez-Pereda, M; Hausch, F; Holsboer, F,期刊：Expert opinion on investigational drugs, 页码：519-535 , 文章类型： Review，,卷期：2011年20-4] Areas covered: The use of corticotropin releasing factor type 1 (CRF1) receptor antagonists for depression is supported by abundant evidence of target validation, the availability of in vitro and in vivo assays and speci... Brivanib alaninate for cancer [作者：Diaz-Padilla, I; Siu, LL,期刊：Expert opinion on investigational drugs, 页码：577-586 , 文章类型： Article，,卷期：2011年20-4] Areas covered: This review provides an updated summary of preclinical and clinical experience with brivanib in cancer. Data presented in abstract form from international conferences or journal articles found with a PubMe... A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2 [作者：Doggrell, SA,期刊：Expert opinion on investigational drugs, 页码：587-590 , 文章类型： Article，,卷期：2011年20-4] Objective/methods: A paper suggesting that inhibitors of Gly2019Ser mutant may be useful in the treatment of Parkinson's disease associated with this mutant is evaluated. Results: Overexpression of the wild-type LRRK2 or... Riociguat for the treatment of pulmonary hypertension [作者：Schermuly, RT; Janssen, W; Weissmann, N; Stasch, JP; Grimminger, F; Ghofrani, HA,期刊：Expert opinion on investigational drugs, 页码：567-576 , 文章类型： Article，,卷期：2011年20-4] Areas covered: This review will help readers understand the mechanism of action of the soluble guanylate cyclase (sGC) stimulator riociguat (BAY 63-2521) and will provide a comprehensive summary regarding efficacy and sa... Update on new drugs in small cell lung cancer [作者：Horn, L; Castellanos, EL; Johnson, DH,期刊：Expert opinion on investigational drugs, 页码：441-455 , 文章类型： Review，,卷期：2011年20-4] Areas covered: This article reviews the results of recent clinical trials that have evaluated targeted agents and novel cytotoxic agents alone or in combination with standard chemotherapy in the treatment of patients wit... Combined neutral endopeptidase inhibitors [作者：Cuculi, F; Erne, P,期刊：Expert opinion on investigational drugs, 页码：457-463 , 文章类型： Review，,卷期：2011年20-4] Areas covered: Different NEP inhibitors have been tested but omapatrilat is the most widely studied in the setting of hypertension, heart failure and chronic angina. We have undertaken a PubMed search on NEP with a speci... Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers [作者：Smith, K; Hopp, M; Mundin, G; Bond, S; Bailey, P; Woodward, J; Palaniappan, K; Church, A; Limb, M; Connor, A,期刊：Expert opinion on investigational drugs, 页码：427-439 , 文章类型： Article，,卷期：2011年20-4] Methods: Fifteen healthy male volunteers received: oxycodone 10 and 20 mg, oxycodone/naloxone 10/5 and 20/10 mg (all as prolonged release tablets) and placebo. Each dose was radiolabelled and administered with a capsule ...